Xolegel Treats Seborrheic Dermatitis

Once-daily application

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

MONDAY, July 31, 2006 (HealthDay News) -- Barrier Therapeutics' treatment for seborrheic dermatitis has been approved by the U.S. Food and Drug Administration, the company said in a statement.

Xolegel (2% ketoconazole, USP) is a once-daily topical gel to treat the skin condition, characterized by a red, scaly, itchy rash that primarily develops on the face, scalp, hairline, eyebrows and trunk.

Seborrheic dermatitis affects 3 percent to 5 percent of the U.S. population, or about 8.5 million people, the company said. The condition often recurs, requiring additional treatment.

More information

To learn more about seborrheic dermatitis, visit the American Academy of Family Physicians.


Last Updated: